Another proof-of-concept trial (n = 50) also suggested that the addition of ablation therapy to anti-PD-1 pembrolizumab or nivolumab increased the objective response rate (ORR) (24% vs. 10% in combination therapy and anti-PD-1 monotherapy, respectively) and achieved a prolonged median OS (16.9 vs. 5.0 months, respectively) with acceptable toxicity profiles in patients with advanced HCC (NCT03939975) [90]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.